Recommended

Novartis selects fourth site for US radioligand manufacturing facility
EC approves Sanofi’s Teizeild for type 1 diabetes
WEBINAR | Harnessing AI for more efficient clinical trials | REGISTER TODAY
Increasing the effectiveness of pharma endotoxin testing | REGISTER NOW
WEBINAR | Practical considerations for aseptic gowning in contamination control strategies
Eur. Ph. publishes new general chapter on quality of data
AbbVie licenses novel bsAb from RemeGen for $5bn
EMA and FDA issue joint AI guidance
J&J’s Caplyta demonstrates phase III promise for major depressive disorder
Harnessing digital PCR for rapid sterility testing | WEBINAR
Realising autonomous pharmaceutical operations – register now
Explore the latest issue here
Complying with USP Chapters 41 and 1251 revisions for pharma quality control | WEBINAR
news

Investment in UK cell and gene therapy manufacturing set to continue

5
SHARES

An additional 6,000m2 of cell and gene therapy manufacturing space is expected to become available within the next 12 months, according to new data.

New data shows that a 60 percent increase in cell and gene manufacturing space reported in 2018 has since become fully functional, reports Cell and Gene Therapy Catapult (CGT Catapult).

 

SECURE YOUR FREE SPOT

 


This webinar to explore rapid sterility testing methods that ensure fast, reliable product release, addressing critical challenges in timely delivery and safety.

Harnessing digital PCR for rapid sterility testing | 18 March 2026 | 3PM

What you’ll discover:

  • Rapid sterility testing methods that address the challenge of lengthy testing times, improving efficiency and ensuring timely product release
  • Insights into how digital PCR technology enhances testing accuracy and sensitivity, detecting contaminants quickly and reliably
  • Real-world case studies on rapid testing implementations in the field of cell and gene therapy

A Q&A session at the end of the webinar gives the audience a chance to ask questions, such as how to implement these technologies effectively.

Register now – it’s free

This growth is also reflected in a surge in jobs in the cell and gene therapy manufacturing industry; numbers have expanded from 150 in 2014, to 500 in 2018 and doubling to over 1,000 staff in 2019, found the researchers.

With significant additional capacity planned, it is essential that skilled personnel are available”

The manufacturing capacity in the UK is due to increase even further in 2020, with around 6,000m2 becoming available. Oxford Biomedica and the CGT Catapult are the main contributors, with 4,200m2 opening at Oxford Biomedica’s new Oxbox facility and a 1,200m2 expansion of the CGT Catapult. Additional space is set to come from expansions at Great Ormond Street, Cobra Biologics, The Rayne Cell Therapy facility at King’s College London, NHS Blood and Transplant (NHSBT) and Scottish National Blood Transfusion Service (SNBTS).

Further extensions are also expected in 2021 from RoslinCT and in 2022 from The University of Birmingham and the Rayne Cell Therapy Facility at King’s College London. With more plans likewise being announced by Karoo Therapeutics, Exmoor Pharma, University of Oxford CBF, MeiraGTx and Immetacyte, cell and gene therapy manufacturing growth is set to continue.

“These facilities coming on stream now are evidence of the acceleration of cell and gene therapies towards commercialisation. With significant additional capacity planned, it is essential that skilled personnel are available. The Advanced Therapies Apprenticeship Community, designed specifically to train and upskill individuals for the sector, setup in partnership with the Medicines Manufacturing Industry Partnership (MMIP), will become increasingly important,” claimed Keith Thompson, Chief Executive Officer CGT Catapult.

 
Share via
Share via